GLP-1 coverage politics is already in the tape - Lilly is still a LONG, but the edge is decaying fast
The Opportunity
The mechanism for a LONG is policy-driven demand durability: broader coverage can expand access and reduce friction for GLP-1 utilisation, which is directionally positive for Lilly. The problem is not the direction; it is the edge. This signal is in propagation_monitor with a spreading lifecycle, which means the market is already seeing and trading the coverage story. That is why the correct Action is INVESTIGATE: directionally resolved, timing window uncertain.
The Timing
Edge decay is the message. In a Bearish 82 regime, even good policy headlines can be drowned by risk-off flows, and the wind bias for longs is adverse (strength 53). What would move this back toward a cleaner TRADE is a new, issuer-specific incremental policy artefact (a concrete payer bulletin with scope, dates, and lives covered) that is not already broadly circulated. Absent that, this is a late-stage narrative where entries matter more than thesis quality.
The Evidence
The hydrated evidence set for this theme includes payer and policy coverage touching GLP-1 access and the broader Lilly-Novo supply and coverage narrative, including boston.com and company-adjacent manufacturing/supply context such as pharmaceutical-technology.com . The fact that these are mainstream-capable outlets is consistent with the lifecycle tag: spreading, not contained.